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Pelizaeus–Merzbacher Disease is an X-linked hypomyelina-
tiing leukodystrophy. We report mutations in the thyroid
hormone transporter gene MCT8 in 11% of 53 families af-
fected by hypomyelinating leukodystrophies of unknown ae-
tiology. The 12 MCT8 mutated patients express initially a
Pelizaeus–Merzbacher-Like disease phenotype with a latter
unusual improvement of magnetic resonance imaging white
matter signal despite absence of clinical progression. This ob-
servation underlines the interest of determining both free T3
and free T4 serum concentrations to screen for MCT8 mu-
tations in young patients (3 y) with a severe Pelizaeus–
Merzbacher-Like disease presentation or older severe men-
tally retarded male patients with “hypomyelinated” regions.
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Pelizaeus–Merzbacher disease (PMD; MIM 312080) is
an X-linked leukodystrophy caused by an inborn error
of myelin formation.1 Clinical features of the classic
form of the disease associate in male patients: nystag-
mus and impaired motor development within the first
months of life followed by ataxia, dystonia, dysarthria,
and progressive spasticity. Intracerebral nerve conduc-
tion is severely impaired, and brain magnetic resonance
imaging (MRI) shows a diffuse “hypomyelinated” pat-
tern. PMD involves the PLP1 gene (Xq22), which en-
codes the main proteins of the central nervous system
(CNS) myelin, the proteolipid proteins. Gene identifi-
cation demonstrated a wide clinical spectrum of PLP-
related disorders in affected male individuals, ranging
from severe PMD, characterized by no developmental
progress and death during the first decade, to
childhood-onset spastic paraplegia (spastic paraplegia
type 2 [SPG2]). The level of motor performance cor-
relates with cognitive abilities, with most PMD pa-
tients failing to achieve walking and to develop
speech.2,3 About 20% of individuals with a typical
PMD phenotype do not have PLP1 molecular defects,
a condition referred as Pelizaeus–Merzbacher–like dis-
ease (PMLD). Genetic heterogeneity of PMD was re-
cently demonstrated by the identification of mutations
in the gap junction 12 (GJA12) gene (PMLD1, MIM
608804). However, GJA12 mutation screening in our
cohort of 114 PMLD patients identified mutations in
only 8% of patients, suggesting a larger genetic heter-
ogeneity.3
The monocarboxylate transporter 8 gene (MCT8, or
SLC16A2, MIM 300095), encoding a thyroid hor-
mone transporter, has been implicated in syndromic
X-linked mental retardation with a wide spectrum of
clinical presentation. The most severe forms are char-
acterized by severe, early-onset hypotonia, nystagmus,
dystonic movements, spastic quadriplegia, and virtually
no motor or speech acquisition.4,5 The mildest forms,
reported both in male and female patients,6 have been
described as Allan–Herndon–Dudley syndrome (AHDS,
MIM 309600). They are characterized by a delay in de-
velopmental milestones related to marked hypotonia,
leading later to spasticity associated with dysarthria,
ataxia, choreoathetoid movements, and facial/neck weak-
ness.7 MRI in MCT8 mutated patients has been initially
reported as normal,4,5 but additional observations sug-
gest at least a cortical atrophy8,9 or even an “hypomyeli-
nated” pattern in young patients.10–13 Abnormal thy-
roid hormone transporter function is reflected by
increased free triiodothyronine (T3), low free thyroxine
(T4), and normal thyroid-stimulating hormone (TSH)
levels in the serum. This profile of thyroid parameters is
now considered as the best marker for MCT8 mutation
screening in mentally retarded patients. Here we de-
scribe the implication of MCT8 mutations in patients
presenting initially with clinical, electrophysiological,
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and MRI features characteristic of PMLD, and demon-
strate the usefulness of thyroid hormone dosages to se-
lect patients for MCT8 mutation screening.
Patients and Methods
Patients
A peculiar thyroid hormone profile (slightly increased free
T3, low free T4, and normal TSH levels) was identified in
the serum of an 8-year-old male patient (632) reevaluated
after an initial diagnosis of PMLD (see the Supplementary
Table). He had severe congenital hypotonia without head
control, multidirectional nystagmus with bobbling move-
ments of the head and trunk with subsequent decrease in
intensity after the first year of life, dystonic movements of
the upper limbs, slow improvement in communication skills,
no behavioral problems, and lack of myelination signal on
brain MRI performed at 1 year of age (Fig 1A). PLP1 gene
analysis performed at 34 months was normal. Follow-up
evaluation at respectively 42 months and 5 years of age
showed improved white matter signal on T1 and T2 se-
quence brain MRI (see Figs 1B, C), and dissociated slowing
of CNS conduction on evoked potentials, contrasting with
the absence of motor or cognitive improvement and worsen-
ing of axial dystonic posture and epileptic features. The ab-
normal thyroid profile associated with this unusual clinical
and MRI evolution for PMLD led us to analyze the MCT8
gene in this patient and allowed to identify a new MCT8
mutation (see Results).
This observation and the similarities of the symptoms re-
ported in PLP1 and MCT8 mutated patients4,5 led us to
further screen PLP1-negative patients from our cohort of un-
determined X-linked “hypomyelinated” leukoencephalopa-
thies and SPG for MCT8 mutation. We selected 52 families
with 1 or more affected boys with no PLP1 mutation. Forty-
four were PMLD families selected according to these criteria:
(1) our published criteria for PMD,1 that is, families includ-
ing only affected boys with an early impairment of motor
development (6 months of life), neurological signs that
were gradually modified by the maturing nervous system
(nystagmus, choreoathetotic movements, ataxia and progres-
sive spasticity), severe decrease in CNS nerve conductions
on multimodal-evoked potentials (brainstem auditory or
somatosensory-evoked potentials, or both), diffuse hypomy-
elination pattern on T1 and T2 brain MRI imaging after 1
year; and (2) absence of mutations in the PLP1 and GJA12
genes. We selected PMLD patients with a severe form (no
motor acquisition or acquisition of only head control) in ac-
cordance with the phenotype of the MCT8-mutated PMLD
patient described earlier. Eight additional families were also
included: one family with a sporadic form of SPG with a
diffuse “hypomyelinated” supratentorial white matter on
brain MRI, four X-linked SPG families with an early onset
(10 years), and three families with predominant X-linked
mental retardation and immature “hypomyelinated” regions
on brain MRI. In the latter two groups of seven X-linked
families, the MCT8 genomic region was not excluded by
haplotype analysis.
MCT8 Gene Analysis
The six exons of the MCT8 gene were analyzed after poly-
merase chain reaction (PCR) amplification by Denaturating
High Performance Liquid Chromatography (DHPLC)
(WAVE System; Transgenomic, Coultaboeuf, France).
Primer sequences, PCR, and DHPLC conditions are avail-
able on request. Sequences of the PCR products demonstrat-
ing abnormal retention times on DHPLC were performed
using the GenomeLab DTCS kit (Beckman Coulter, Fuller-
tone, CA) and analyzed on a capillary CEQ 2000XL DNA
Analysis System (Beckman Coulter) with the CEQ 8000
software. Segregation of the mutations in the families and
Fig 1. Brain magnetic resonance imaging (MRI) of MCT8-
mutated patients. (A–C) Follow-up of T2-weighted imaging
in Patient 362 at 1 (A), 3 (B), and 5 (C) years of age. MRI
demonstrates a progressive improvement of the white matter
(WM) signal between 1 and 5 years of age, reflecting a myeli-
nation delay rather than a persistent hypomyelination. The
corpus callosum appears similarly atrophic at the different ages.
(D) T2-weighted imaging demonstrating in Patient 719 at 7
months of age an abnormal diffuse hypersignal of the WM.
(E) The abnormal WM signal is restricted to the periventricu-
lar regions in Patient 17.2 at 4 years of age. (F) For Patient
17.1, at 10 years of age, the WM is atrophic with a ventricu-
lar dilatation but a normal signal. Atrophy of the corpus cal-
losum is clearly present in the three patients (D–F). (G–I)
MR images for Patient 664 (T1 [G], T2 [H], and fluid-
attenuated inversion recovery [FLAIR] [I]) at 10 years old
showing only a mild hypersignal of the periventricular WM on
the FLAIR sequence associated with a mild frontal cortical
atrophy.
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Direct sequencing of the PCR product demonstrating
an abnormal retention time on DHPLC for Patient
632 identified a novel nonsense MCT8 mutation,
c.1558CT, predicted to lead to a truncated protein,
p.Gln520X, missing the 93 last amino acids of the
MCT8 11th and 12th transmembrane domains. Anal-
ysis of the MCT8 coding sequences in the cohort of 52
patients identified 5 mutations (see Fig 2). Among
those, 4 were new and not found in 300 male healthy
white control subjects, including 1 frameshift muta-
tion (c.1826delC [p.Pro609LeufsX70]), 1 deletion
(encompassing exons 2–4), and 2 missense mutations
(c.661GA [p.Gly221Arg], c.962CT [p.Pro321Leu]).
Amino acids affected by those new missense mutations
are localized respectively in transmembrane domains 2
and 5, and are conserved in the five species evaluated
(see Fig 2). In addition, both PolyPhen (http://coot.em-
bl.de/PolyPhen/) and SNPs3D (http://www.snps3d.org)
software predict damaging functional consequences of
the p.Pro321Leu and p.Gly221Arg transitions. The last
mutation (c.1003CT [p.Gln335X]) was a previously
reported nonsense mutation.14
Clinical Characteristics of MCT8 Mutated Patients
The clinical characteristics of the 12 affected patients
from the 6 MCT8 mutated families are summarized in
the Supplementary Table. All patients presented early
(6 months) symptoms related to poor motor acqui-
sitions associated with early nystagmus in four and
choreoathetosis or ataxia in seven. All experienced de-
velopment of severe spastic quadriplegia or paraplegia
associated in eight cases with generalized or axial dys-
tonia. Motor and cognitive acquisitions were limited
with no or poor head control and absence of words in
all affected patients except in Family 1371 with af-
fected boys who acquired with delay the sitting posi-
tion or walking with help. In the latter family, survival
was prolonged, whereas in Families 17 and 210, pa-
tients died in the first decade from severe neurovegeta-
tive dysfunction (achalasia, apneas, swallowing and
feeding difficulties, sudden death). A myelin defect af-
fecting the first myelinated areas (brainstem, internal
capsule, and corpus callosum) with a thin corpus cal-
losum was observed on brain MRI performed before 2
years of age (see Figs 1A, D), whereas at an older age,
only periventricular regions appeared poorly myelin-
ated (see Figs 1E, F, I), contrasting with an absence of
clinical improvement. Dissociated alterations of CNS
conductions without peripheral involvement were no-
ticed. Thyroid parameters in the three patients avail-
able for serum dosages demonstrated increased T3, de-
creased T4, and normal TSH levels.
Neither mental retardation nor neuromotor abnor-
mal presentation was reported for the carrier mothers,
and only behavioral problems were noticed in all
mothers from Family 17. Brain MRI of the mother of
Patient 632 was normal, but molecular analysis has
demonstrated that she was not carrying the mutation
that may therefore correspond to a neo mutation (see
Fig 2).
Discussion
MCT8 mutations were found in 11% of our 53 fami-
lies with male members affected with a severe form of
undetermined “hypomyelinated” leukodystrophies. The
six index cases had clinical presentations suggestive of
severe forms of PMLD with early signs of myelination
impairment (hypotonia, nystagmus, ataxia/choreoathe-
totic movements, abnormal evoked potentials, and hy-
pomyelinated pattern of the brain MRI) and severe ax-
onal dysfunction (progressive severe spastic paraplegia,
dystonia, and central neurovegetative signs). However,
the supratentorial myelinated areas and the mild CNS
conduction abnormalities noted before 2 years of age
in our MCT8 mutated patients are in favor of a less
severe myelin defect, as usually observed in the mild-
est forms of PLP1 or GJA12 mutated patients. The
favorable evolution of MRI during patients’ follow-up
and the mildly hypomyelinated pattern observed in
older MCT8 mutated patients confirmed that MCT8
mutations are responsible for a severe myelination de-
lay rather than a permanent myelin defect, as ob-
served in PLP1 or GJA12 hypomyelinating disorders.
Abnormal serum thyroid hormone profiles, with in-
creased free T3, decreased free T4, and normal TSH
concentrations, appear to be a useful marker to screen
for MCT8 mutations in patients with myelination
impairment.15
MCT8 mutations appear to induce a deficiency in
T3 cell entry despite high circulating T3 concentra-
tions.15 Absence of neurological improvement observed
in MCT8-mutated patients even with a T4 substitutive
therapy confirmed the specific need for T3 in the
brain. Based on specific neuronal Mct8 expression re-
ported in mice,16 a defect in T3 hormone in neurons is
considered responsible for the severe mental and motor
deficiencies observed in MCT8-deficient patients.15
The similar clinical characteristics found in MCT8-
and PLP1-mutated patients, despite an apparent myeli-
nation delay rather than a permanent myelin defect on
MRI of MCT8-mutated patients, suggest a link be-
tween MCT8 and oligodendrocyte maturation.
Whether MCT8 loss of function affects myelination di-
rectly via T3 transport impairment in oligodendrocytes
or indirectly via alterations of myelin-axon interactions,
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or both, remain to be addressed by further experi-
ments.
In conclusion, our report underlines the interest of
determining serum thyroid parameters including both
T3 and T4 concentrations to screen for MCT8 muta-
tions in either young patients with a severe PMLD pre-
sentation or older male patients with severe mental and
motor retardation with “hypomyelinated” regions on
Fig 2. Pedigree of hypomyelinated families with MCT8 mutation. Arrows indicate the index case of each family that was first analyzed
for MCT8 mutation. Small black circles indicate mothers with an established carrier status. Ages of death of the affected boys are shown
in parentheses. Mutation segregation in Families 210, 664, 719, and 1371 is in accordance with an X-linked mode of inheritance. For
Families 17 and 1371, suggestive logarithm of odds score values (Zmax  2.59 and 1.2, respectively) have been previously obtained by
linkage analysis for regions encompassing the MCT8 gene. Exon 2 to 4 deletion in Family 17 was characterized after migration on a 2100
Bioanalyzer (Agilent Palo Alto, CA.) of duplex polymerase chain reaction (PCR) products. After coamplification of exon 6 with either exon
2, 3, or 4, it appears that exons 2, 3, and 4 never amplify from the affected patient’s DNA (A), whereas exon 6 does, as well as exons 1
and 5. All expected coamplifications were obtained with control DNA (C). Similar results were obtained for Patient 17.3, confirming in
this family the deletion of the genomic sequence encoding exons 2 to 4. For amino acids (AAs) affected by new missense mutations, that is,
Gly221 (Family 719) and Pro321 (Family 210) localized respectively in transmembrane (TM) domains 2 and 5, analysis of AA conserva-
tion between human and other species (macaque: Macaca mulatta [Mam], mouse: Mus musculus [Mum], rat: Rattus norvegicus [Rn],
and chicken: Gallus gallus [Gg]), demonstrates that both AAs are highly conserved.
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MRI. The 11% of MCT8-mutated patients found in
our group of severe PMLD suggest a role of MCT8
and/or free T3 in myelin production and axon-glial in-
teractions.
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